Clinical trial • Phase III • Oncology
HAFNIUM OXIDE for Locally advanced head and neck squamous cell carcinoma
Phase III trial of HAFNIUM OXIDE for Locally advanced head and neck squamous cell carcinoma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Locally advanced head and neck squamous cell carcinoma
- Trial Stage
- Phase III
- Drug Modality
- Other|Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 05-03-2025
- First CTIS Authorization Date
- 25-06-2025
Trial design
Randomised, rt ± cetuximab (investigator's choice of radiotherapy alone or radiotherapy in combination with cetuximab) — comparator arm: radiotherapy with or without cetuximab; no dose/schedule specified in the available record.-controlled Phase III trial in Belgium, Germany, Hungary and others.
- Randomised
- Yes
- Comparator
- RT ± cetuximab (Investigator's choice of radiotherapy alone or radiotherapy in combination with cetuximab) — comparator arm: radiotherapy with or without cetuximab; no dose/schedule specified in the available record.
- Target Sample Size
- 307
Eligibility
Recruits 307 isVulnerablePopulationSelected: false; no specific vulnerable population considerations or assent/consent handling described in the available record..
- Vulnerable Population
- isVulnerablePopulationSelected: false; no specific vulnerable population considerations or assent/consent handling described in the available record.
Inclusion criteria
- {"criterion_text":"- 1. Age ≥ 60 years old\n- 2. Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab\n- 3. Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC\n- 4. One primary tumor lesion amendable for intratumoral injection\n- \"5. Ineligible to receive platinum-based chemotherapy with radiation: a.\tEstimated creatinine clearance ≥30 and <50 mL/min (per Cockcroft-Gault equation), Grade ≥2 hearing loss or tinnitus, Grade ≥2 peripheral neuropathy, ECOG Performance Status 2, New York Heart Association Class 3 b.\tAge 70-74 years old with Geriatric 8 (G8) score ≤ 14 c.\tAge ≥ 75 years old\""}
Exclusion criteria
- {"criterion_text":"- 1.\tCarcinoma of the nasopharynx, paranasal sinus(es), salivary gland, thyroid gland, or unknown primary\n- 2.\tNon-squamous cell histology\n- 3.\tClinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC\n- 4.\tLoco-regionally recurrent head & neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy\n- 5.\tPrior or concurrent primary malignancy (including second synchronous head & neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent\n- 6.\tOngoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Progression-free survival (PFS): time from randomization to loco-regional recurrence, loco-regional progression, distant progression, or death from any cause, whichever occurs first","definition_or_measurement_approach":"Time from randomization to loco-regional recurrence, loco-regional progression, distant progression, or death from any cause (whichever occurs first) as stated: \"Progression-free survival (PFS): time from randomization to loco-regional recurrence, loco-regional progression, distant progression, or death from any cause, whichever occurs first\"."}
Recruitment
- Planned Sample Size
- 307
- Recruitment Window Months
- 37
- Consent Approach
- Informed consent obtained using Subject Information Sheets (SIS) and Informed Consent Forms (ICF); country- and language-specific SIS/ICF documents are provided (examples: BE English/Dutch/French, DE German, HU Hungarian, RO Romanian, CZ Czech, ES Spanish, FR French, PT Portuguese, AT German). No details on assent or guardian consent are provided; trial population are adults (age ≥60).
Methods
- Use of recruitment materials (documented in submission): patient letters, patient brochures, caregiver brochures, study posters, flipcharts/ICF flipcharts, participant clinical trial overview documents — country-specific versions available (examples in the record for Belgium, Germany, Hungary, Romania, Czechia, Spain, France, Portugal, Austria, Greece).
Geography
- Total Number Of Sites
- 54
- Total Number Of Participants
- 194
Belgium
- Earliest CTIS Part Ii Submission Date
- 26-05-2025
- Latest Decision Or Authorization Date
- 15-09-2025
- Processing Time Days
- 112
- Number Of Sites
- 3
- Number Of Participants
- 10
Sites
- Site Name
- UZ Leuven
- Department Name
- Radiotherapy-Oncology
- Principal Investigator Name
- Sandra Nuyts
- Principal Investigator Email
- sandra.nuyts@uzleuven.be
- Contact Person Name
- Sandra Nuyts
- Contact Person Email
- sandra.nuyts@uzleuven.be
- Site Name
- Cliniques Universitaires Saint-Luc
- Department Name
- Cancer et Hématologie adulte et pédiatrique
- Principal Investigator Name
- Eléonore Longton
- Principal Investigator Email
- eleonore.longton@uclouvain.be
- Contact Person Name
- Eléonore Longton
- Contact Person Email
- eleonore.longton@uclouvain.be
- Site Name
- Grand Hopital De Charleroi
- Department Name
- Service d’Oncologie-Hématologie
- Principal Investigator Name
- Benjamin Ledoux
- Principal Investigator Email
- benjamin.ledoux@ghdc.be
- Contact Person Name
- Benjamin Ledoux
- Contact Person Email
- benjamin.ledoux@ghdc.be
Germany
- Earliest CTIS Part Ii Submission Date
- 26-03-2025
- Latest Decision Or Authorization Date
- 07-08-2025
- Processing Time Days
- 134
- Number Of Sites
- 7
- Number Of Participants
- 15
Sites
- Site Name
- Rostock University Medical Center
- Department Name
- Clinic and Polyclinic for Radiation Therapy (“Klinik und Poliklinik für Strahlentherapie”)
- Principal Investigator Name
- Guido Hildebrandt
- Principal Investigator Email
- strahlentherapie@med.uni-rostock.de
- Contact Person Name
- Guido Hildebrandt
- Contact Person Email
- strahlentherapie@med.uni-rostock.de
- Site Name
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
- Department Name
- Department of Radiation Oncology
- Principal Investigator Name
- Stephanie E. Combs
- Principal Investigator Email
- stephanie.combs@tum.de
- Contact Person Name
- Stephanie E. Combs
- Contact Person Email
- stephanie.combs@tum.de
- Site Name
- University Hospital Cologne AöR
- Department Name
- Department of Othorinolaryngology, Head and Neck Surgery
- Principal Investigator Name
- Peter Klußmann
- Principal Investigator Email
- peter.klussmann@uk-koeln.de
- Contact Person Name
- Peter Klußmann
- Contact Person Email
- peter.klussmann@uk-koeln.de
- Site Name
- Universitaetsklinikum Mannheim GmbH
- Department Name
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie (HNO)
- Principal Investigator Name
- Annette Affolter
- Principal Investigator Email
- annette.affolter@umm.de
- Contact Person Name
- Annette Affolter
- Contact Person Email
- annette.affolter@umm.de
- Site Name
- Justus-Liebig-Universitaet Giessen
- Department Name
- Ear, nose and throat clinic (“Hals- Nasen- und Ohrenklinik”)
- Principal Investigator Name
- Christine Langer
- Principal Investigator Email
- christine.langer@hno.med.uni-giessen.de
- Contact Person Name
- Christine Langer
- Contact Person Email
- christine.langer@hno.med.uni-giessen.de
- Site Name
- Universitaetsklinikum Jena KöR
- Department Name
- Department of Ear, Nose and Throat Medicine (“Klinik für Hals-, Nasen- und Ohrenheilkunde”)
- Principal Investigator Name
- Orlando Guntinas-Lichius
- Principal Investigator Email
- orlando.guntinas@med.uni-jena.de
- Contact Person Name
- Orlando Guntinas-Lichius
- Contact Person Email
- orlando.guntinas@med.uni-jena.de
- Site Name
- Medizinische Hochschule Hannover
- Department Name
- Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
- Principal Investigator Name
- Philipp Ivanyi
- Principal Investigator Email
- haematologie.onkologie@mh-hannover.de
- Contact Person Name
- Philipp Ivanyi
- Contact Person Email
- haematologie.onkologie@mh-hannover.de
Hungary
- Earliest CTIS Part Ii Submission Date
- 29-04-2025
- Latest Decision Or Authorization Date
- 28-08-2025
- Processing Time Days
- 121
- Number Of Sites
- 3
- Number Of Participants
- 20
Sites
- Site Name
- Orszagos Onkologiai Intezet
- Department Name
- Sugárterápiás Központ, Sugárterápiás Osztály
- Principal Investigator Name
- Zoltán TAKÁCSI-NAGY
- Principal Investigator Email
- takacsi.zoltan@oncol.hu
- Contact Person Name
- Zoltán TAKÁCSI-NAGY
- Contact Person Email
- takacsi.zoltan@oncol.hu
- Site Name
- University Of Szeged
- Department Name
- Szent-György Albert Klinikai Központ Onkoterápiás Klinika)
- Principal Investigator Name
- Katalin HIDEGHÉTY
- Principal Investigator Email
- katalin.hideghety@gmail.com
- Contact Person Name
- Katalin HIDEGHÉTY
- Contact Person Email
- katalin.hideghety@gmail.com
- Site Name
- Central Hospital Of Northern Pest Military Hospital
- Department Name
- Fül-Orr-Gége, Fej- és Nyaksebészeti Osztály
- Principal Investigator Name
- Frigyes HELFFERICH
- Principal Investigator Email
- frigyes.helfferich@gmail.com
- Contact Person Name
- Frigyes HELFFERICH
- Contact Person Email
- frigyes.helfferich@gmail.com
Romania
- Earliest CTIS Part Ii Submission Date
- 26-03-2025
- Latest Decision Or Authorization Date
- 08-09-2025
- Processing Time Days
- 166
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
- Department Name
- Radiotherapy Department II
- Principal Investigator Name
- Rodica Maricela Anghel
- Principal Investigator Email
- contact@iob.ro
- Contact Person Name
- Rodica Maricela Anghel
- Contact Person Email
- contact@iob.ro
Czechia
- Earliest CTIS Part Ii Submission Date
- 25-11-2025
- Latest Decision Or Authorization Date
- 22-12-2025
- Processing Time Days
- 27
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Fakultni Nemocnice Bulovka
- Department Name
- Ustav radiacni onkologie
- Principal Investigator Name
- Petra Holeckova
- Principal Investigator Email
- petra.holeckova@bulovka.cz
- Contact Person Name
- Petra Holeckova
- Contact Person Email
- petra.holeckova@bulovka.cz
Spain
- Earliest CTIS Part Ii Submission Date
- 26-03-2025
- Latest Decision Or Authorization Date
- 04-12-2025
- Processing Time Days
- 253
- Number Of Sites
- 15
- Number Of Participants
- 30
Sites
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Head and Neck and Cancer, Gastrointestinal Cancer Unit
- Principal Investigator Name
- Luka Mihic
- Principal Investigator Email
- lmihic@hmhospitales.com
- Contact Person Name
- Luka Mihic
- Contact Person Email
- lmihic@hmhospitales.com
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Radiation Oncology
- Principal Investigator Name
- Jordi Giralt
- Principal Investigator Email
- jorgeluis.giralt@vallhebron.cat
- Contact Person Name
- Jordi Giralt
- Contact Person Email
- jorgeluis.giralt@vallhebron.cat
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Medical Oncology
- Principal Investigator Name
- Imanol Martínez Salas
- Principal Investigator Email
- imanol.martinez@quironsalud.es
- Contact Person Name
- Imanol Martínez Salas
- Contact Person Email
- imanol.martinez@quironsalud.es
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Radiation oncology
- Principal Investigator Name
- Jorge Contreras Martínez
- Principal Investigator Email
- jorgecontrerasmartinez@gmail.com
- Contact Person Name
- Jorge Contreras Martínez
- Contact Person Email
- jorgecontrerasmartinez@gmail.com
- Site Name
- Hospital Universitario De Cruces
- Department Name
- Radiotherapeutic Oncology
- Principal Investigator Name
- Jon Cacicedo Fernandez Bobadilla
- Principal Investigator Email
- joncaci@gmail.com
- Contact Person Name
- Jon Cacicedo Fernandez Bobadilla
- Contact Person Email
- joncaci@gmail.com
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Medical Oncology
- Principal Investigator Name
- Marta Sotelo
- Principal Investigator Email
- Marta.sotelo@sc.salud.es
- Contact Person Name
- Marta Sotelo
- Contact Person Email
- Marta.sotelo@sc.salud.es
- Site Name
- Institut Catala D'oncologia
- Department Name
- Radiation Oncology
- Principal Investigator Name
- Isabel Linares Galiana
- Principal Investigator Email
- ilinaresgaliana@iconcologia.net
- Contact Person Name
- Isabel Linares Galiana
- Contact Person Email
- ilinaresgaliana@iconcologia.net
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- Medical Oncology
- Principal Investigator Name
- Hector Aguilar Andino
- Principal Investigator Email
- haguilar@fivo.org
- Contact Person Name
- Hector Aguilar Andino
- Contact Person Email
- haguilar@fivo.org
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Medical Oncology, Head and Neck and Tyroid Unit
- Principal Investigator Name
- Izaskun Valduvieco
- Principal Investigator Email
- Ivalduvi@clinic.cat
- Contact Person Name
- Izaskun Valduvieco
- Contact Person Email
- Ivalduvi@clinic.cat
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Medical Oncology
- Principal Investigator Name
- Marta Sotelo
- Principal Investigator Email
- Marta.sotelo@sc.salud.es
- Contact Person Name
- Marta Sotelo
- Contact Person Email
- Marta.sotelo@sc.salud.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Medical Oncology
- Principal Investigator Name
- Mª José Flor Oncala
- Principal Investigator Email
- mariajflor@hotmail.com
- Contact Person Name
- Mª José Flor Oncala
- Contact Person Email
- mariajflor@hotmail.com
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Oral and Maxillofacial Surgery
- Principal Investigator Name
- Santiago Ochandiano
- Principal Investigator Email
- santiago.ochandiano@salud.madrid.org
- Contact Person Name
- Santiago Ochandiano
- Contact Person Email
- santiago.ochandiano@salud.madrid.org
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology
- Principal Investigator Name
- Lara Carmen Iglesias
- Principal Investigator Email
- laraiglesias@hotmail.com
- Contact Person Name
- Lara Carmen Iglesias
- Contact Person Email
- laraiglesias@hotmail.com
- Site Name
- Hospital Universitario Lucus Augusti
- Department Name
- Radiation Oncology
- Principal Investigator Name
- Alicia Folgar Torres
- Principal Investigator Email
- alicia.folgar.torres@sergas.es
- Contact Person Name
- Alicia Folgar Torres
- Contact Person Email
- alicia.folgar.torres@sergas.es
- Site Name
- Hospital Clinico Universitario Lozano Blesa
- Department Name
- Medical Oncology
- Principal Investigator Name
- Julio Jose Lambea
- Principal Investigator Email
- jjlambea@salud.aragon.es
- Contact Person Name
- Julio Jose Lambea
- Contact Person Email
- jjlambea@salud.aragon.es
Austria
- Earliest CTIS Part Ii Submission Date
- 17-06-2025
- Latest Decision Or Authorization Date
- 30-01-2026
- Processing Time Days
- 227
- Number Of Sites
- 3
- Number Of Participants
- 18
Sites
- Site Name
- Ordensklinikum Linz GmbH
- Department Name
- Department of ENT, head and neck surgery (HNO, Kopf- und Halschirurgie)
- Principal Investigator Name
- Andreas Strobl
- Principal Investigator Email
- andreas.strobl@ordensklinikum.at
- Contact Person Name
- Andreas Strobl
- Contact Person Email
- andreas.strobl@ordensklinikum.at
- Site Name
- University Hospital Graz
- Department Name
- Clinical Department of General ENT (Klinische Abteilung für Allgemeine HNO)
- Principal Investigator Name
- Dietmar Thurnher
- Principal Investigator Email
- dietmar.thurnher@medunigraz.at
- Contact Person Name
- Dietmar Thurnher
- Contact Person Email
- dietmar.thurnher@medunigraz.at
- Site Name
- Medical University Of Vienna
- Department Name
- Clinical Department of Oncology (“Klinische Abteilung für Onkologie”)
- Principal Investigator Name
- Thorsten Füreder
- Principal Investigator Email
- thorsten.fuereder@meduniwien.ac.at
- Contact Person Name
- Thorsten Füreder
- Contact Person Email
- thorsten.fuereder@meduniwien.ac.at
France
- Earliest CTIS Part Ii Submission Date
- 23-05-2025
- Latest Decision Or Authorization Date
- 12-01-2026
- Processing Time Days
- 234
- Number Of Sites
- 16
- Number Of Participants
- 65
Sites
- Site Name
- Centre Hospitalier Universitaire De Saint Etienne
- Department Name
- Radiology
- Principal Investigator Name
- Eric Jadaud
- Principal Investigator Email
- eric.jadaud@chu-st-etienne.fr
- Contact Person Name
- Eric Jadaud
- Contact Person Email
- eric.jadaud@chu-st-etienne.fr
- Site Name
- Oncopole Claudius Regaud
- Department Name
- Radiation oncology
- Principal Investigator Name
- Céline DALMASSO
- Principal Investigator Email
- dalmasso.celine@iuct-oncopole.fr
- Contact Person Name
- Céline DALMASSO
- Contact Person Email
- dalmasso.celine@iuct-oncopole.fr
- Site Name
- Centre Hospitalier Universitaire De Rennes
- Department Name
- ENT and cervical facial surgery department
- Principal Investigator Name
- Franck Jegoux
- Principal Investigator Email
- franck.jegoux@chu-rennes.fr
- Contact Person Name
- Franck Jegoux
- Contact Person Email
- franck.jegoux@chu-rennes.fr
- Site Name
- Centre Francois Baclesse
- Department Name
- Radiation Oncology
- Principal Investigator Name
- Juliette Thariat
- Principal Investigator Email
- j.thariat@baclesse.unicancer.fr
- Contact Person Name
- Juliette Thariat
- Contact Person Email
- j.thariat@baclesse.unicancer.fr
- Site Name
- Centre Hospitalier Regional Et Universitaire De Brest
- Department Name
- Radiotherapy
- Principal Investigator Name
- Ulrike Schick
- Principal Investigator Email
- ulrike.schick@chu-brest.fr
- Contact Person Name
- Ulrike Schick
- Contact Person Email
- ulrike.schick@chu-brest.fr
- Site Name
- Institut De Cancerologie De Lorraine
- Department Name
- Oncology-Radiotherapy
- Principal Investigator Name
- Sophie Renard
- Principal Investigator Email
- s.renard@nancy.unicancer.fr
- Contact Person Name
- Sophie Renard
- Contact Person Email
- s.renard@nancy.unicancer.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- ENT (Ear, Nose, and Throat) and Head and Neck Surgery Department
- Principal Investigator Name
- Emmanuelle Fabiano
- Principal Investigator Email
- emmanuelle.fabiano@aphp.fr
- Contact Person Name
- Emmanuelle Fabiano
- Contact Person Email
- emmanuelle.fabiano@aphp.fr
- Site Name
- Institut Curie
- Department Name
- ENT and cervico facial surgery
- Principal Investigator Name
- Maria Lesnik
- Principal Investigator Email
- maria.lesnik@curie.fr
- Contact Person Name
- Maria Lesnik
- Contact Person Email
- maria.lesnik@curie.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Radiotherapy
- Principal Investigator Name
- Thanh-Van Nguyen
- Principal Investigator Email
- th.nguyen@gustaveroussy.fr
- Contact Person Name
- Thanh-Van Nguyen
- Contact Person Email
- th.nguyen@gustaveroussy.fr
- Site Name
- Centre Henri Becquerel
- Department Name
- Radiotherapy
- Principal Investigator Name
- Sébastien Thureau
- Principal Investigator Email
- sebastien.thureau@chb.unicancer.fr
- Contact Person Name
- Sébastien Thureau
- Contact Person Email
- sebastien.thureau@chb.unicancer.fr
- Site Name
- Centr Georges Francois Leclerc
- Department Name
- Radiotherapy
- Principal Investigator Name
- Noémie VULQUIN
- Principal Investigator Email
- nvulquin@cgfl.fr
- Contact Person Name
- Noémie VULQUIN
- Contact Person Email
- nvulquin@cgfl.fr
- Site Name
- Centre Oscar Lambret
- Department Name
- Radiotherapy
- Principal Investigator Name
- Isaure Roquette
- Principal Investigator Email
- i-roquette@o-lambret.fr
- Contact Person Name
- Isaure Roquette
- Contact Person Email
- i-roquette@o-lambret.fr
- Site Name
- Centre Medico Chirurgical Ambroise Pare Hartmann
- Department Name
- Radiation Oncology
- Principal Investigator Name
- Jean-Michel Vannetzel
- Principal Investigator Email
- dr.vannetzel@gmail.com
- Contact Person Name
- Jean-Michel Vannetzel
- Contact Person Email
- dr.vannetzel@gmail.com
- Site Name
- Centre Hospitalier Universitaire Amiens Picardie
- Department Name
- Medical oncology and radiotherapy department
- Principal Investigator Name
- Etienne Fessart
- Principal Investigator Email
- fessart.etienne@chu-amiens.fr
- Contact Person Name
- Etienne Fessart
- Contact Person Email
- fessart.etienne@chu-amiens.fr
- Site Name
- Centre Hospitalier Regional De Marseille
- Department Name
- Medical Oncology
- Principal Investigator Name
- Sébastien Salas
- Principal Investigator Email
- sebastien.salas@ap-hm.fr
- Contact Person Name
- Sébastien Salas
- Contact Person Email
- sebastien.salas@ap-hm.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Radiotherapy
- Principal Investigator Name
- Charles Dupin
- Principal Investigator Email
- charles.dupin@chu-bordeaux.fr
- Contact Person Name
- Charles Dupin
- Contact Person Email
- charles.dupin@chu-bordeaux.fr
Portugal
- Earliest CTIS Part Ii Submission Date
- 05-05-2025
- Latest Decision Or Authorization Date
- 19-02-2026
- Processing Time Days
- 290
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Hospital Cuf Descobertas S.A.
- Department Name
- Oncology
- Principal Investigator Name
- Diogo Alpuim Costa
- Principal Investigator Email
- diogo.costa@jmellosaude.pt
- Contact Person Name
- Diogo Alpuim Costa
- Contact Person Email
- diogo.costa@jmellosaude.pt
- Site Name
- Unidade Local De Saude De Gaia/Espinho E.P.E.
- Department Name
- Medical oncology
- Principal Investigator Name
- Joana Marinho
- Principal Investigator Email
- joana.marinho@ulsge.min-saude.pt
- Contact Person Name
- Joana Marinho
- Contact Person Email
- joana.marinho@ulsge.min-saude.pt
Greece
- Earliest CTIS Part Ii Submission Date
- 20-05-2025
- Latest Decision Or Authorization Date
- 10-03-2026
- Processing Time Days
- 294
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- University General Hospital Attikon
- Department Name
- Internal Medicine Clinic / Oncology Unit
- Principal Investigator Name
- Amanda Psyrri
- Principal Investigator Email
- psyrri237@yahoo.com
- Contact Person Name
- Amanda Psyrri
- Contact Person Email
- psyrri237@yahoo.com
- Site Name
- Athens Medical Center S.A.
- Department Name
- Oncology Department
- Principal Investigator Name
- Sofia Baka
- Principal Investigator Email
- bakasofia@hotmail.com
- Contact Person Name
- Sofia Baka
- Contact Person Email
- bakasofia@hotmail.com
- Site Name
- General University Hospital Of Larissa
- Department Name
- Oncology Department / 1st Internal Medicine Division
- Principal Investigator Name
- Athanasios Kotsakis
- Principal Investigator Email
- thankotsakis@hotmail.com
- Contact Person Name
- Athanasios Kotsakis
- Contact Person Email
- thankotsakis@hotmail.com
Sponsor
Primary sponsor
- Full Name
- Johnson & Johnson Enterprise Innovation Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Icon Clinical Research LLC
- Responsibilities
- ECG holter data analysis / review for the sub-study
- Name
- Icon Clinical Research Limited
- Responsibilities
- code 6
- Name
- Fortrea Inc.
- Responsibilities
- code 8
- Name
- Clinical Services International LLC
- Responsibilities
- Provider of non-IMP medication
Third parties
- {"country":"Belgium","full_name":"Cerba Research","duties_or_roles":"code 4","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"United States","full_name":"Icon Clinical Research LLC","duties_or_roles":"ECG holter data analysis / review for the sub-study","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"Medidata Solutions International Limited","duties_or_roles":"codes 3 and 7","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Quipment","duties_or_roles":"Equipment rental","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Imaging Endpoints II LLC","duties_or_roles":"Central imaging review","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Creapharm Clinical Supplies","duties_or_roles":"code 14","organisation_type":"Pharmaceutical company"}
- {"country":"Belgium","full_name":"Quality Assistance","duties_or_roles":"code 4","organisation_type":"Pharmaceutical company"}
- {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"code 6","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Fortrea Inc.","duties_or_roles":"code 8","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Aquilab By Coexya","duties_or_roles":"Radiotherapy QA service","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Clinical Services International LLC","duties_or_roles":"Provider of non-IMP medication","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"reimbursement of study subject expenses","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- JNJ-90301900
- Active Substance
- HAFNIUM OXIDE
- Modality
- Other
- Routes Of Administration
- INTRATUMORAL USE
- Route
- INTRATUMORAL USE
- Authorisation Status
- Investigational (no marketing authorisation provided in record)
- Investigational Product Name
- Erbitux 5 mg/mL solution for infusion
- Active Substance
- CETUXIMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS USE
- Authorisation Status
- Authorised (marketing authorisation EU/1/04/281/003 listed)
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- EZABENLIMAB for Locally advanced head and neck squamous cell carcinoma
- JNJ-90301900 for Locally advanced head and neck squamous cell carcinoma
- Lenvatinib for Locally advanced head and neck squamous cell carcinoma
- PUCOTENLIMAB for Locally advanced head and neck squamous cell carcinoma
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer